Get the answers you need.
Not automatically. A scaffold can provide structural support for regenerative processes, but the presence of a scaffold alone does not establish a regenerative clinical outcome. Claims of regeneration should reflect the biological endpoint demonstrated by the available evidence.
CXU™ is specifically designed to flow into irregular tissue spaces before gelling near body temperature, allowing the scaffold to conform to complex wound geometry in preclinical applications.
Some preclinical studies have reported findings related to organized healing and scarring, but CXU™ has not yet been shown to reduce scarring in humans.
CXU™ is being investigated for aesthetic applications including soft-tissue changes associated with significant weight loss, but it is not currently approved or cleared for this or any aesthetic indication. Safety and effectiveness in humans have not been established.
ECM-based biomaterials can be investigated as materials for biofabrication and tissue-engineering applications. Conexeu is exploring CXU™ as a printable collagen-based ECM platform for 3D tissue structures.
Yes. Conexeu is evaluating the same foundational ECM technology across multiple tissue environments, including human and veterinary applications. Each use still requires application-specific development, evidence and regulatory pathways.
Conexeu is investigating CXU™ for periodontal and implant-related applications because its flowable formulation can conform to irregular spaces before setting into a scaffold. Clinical utility in humans has not yet been established.
CXU™ is designed as a temporary scaffold that supports host tissue in-growth and remodeling rather than remaining as permanent implanted material. Whether and how that translates into clinical outcomes in humans still requires clinical evaluation.
Human inflammatory response to CXU™ has not been established. Published preclinical studies related to the underlying platform have evaluated local biocompatibility and host response, but animal and laboratory findings do not establish safety or inflammatory performance in humans.
Preclinical research is focused on CXU™ as a structural ECM scaffold supporting tissue integration and remodeling. Human clinical studies will be needed to characterize specific biological and clinical effects.
No human clinical performance has been established. The B.R.E.A.S.T. program remains preclinical and will require further development and applicable regulatory review before any clinical use.
CXU™ remains in preclinical development. Its safety and effectiveness have not yet been established in human clinical studies.
Aging can alter the composition, organization and mechanical properties of the ECM, contributing to changes in tissue structure and integrity. Conexeu is investigating whether restoring structural support could help create more favorable conditions for tissue restoration.
Rapid or substantial weight loss can reduce underlying fat and muscle volume, contributing to deflation, laxity and changes in facial or body contours. Conexeu is exploring tissue-restoration approaches for soft-tissue changes that can follow significant weight loss.
Rapid or substantial weight loss can reduce subcutaneous fat and, in some individuals, lean-tissue volume, contributing to changes in support, laxity and contour. The extent and mechanisms of associated ECM changes remain an active area of study. Conexeu is exploring an ECM-based approach for soft-tissue changes associated with aging and significant weight loss.
Cells attach to and interact with the ECM around them. That matrix provides physical support and participates in signaling processes that influence cell migration, organization and behavior.
As Conexeu uses the term, bioregeneration begins with establishing a supportive structural environment in which tissue repair and remodeling can occur. In tissue-engineering models, a scaffold may support cell migration, vascular interaction and tissue organization; whether a specific product produces regenerative clinical outcomes requires product-specific evidence.
CXU™ is being developed on the scaffold side of the framework: as a temporary, collagen-based extracellular matrix designed to provide structural support while host tissue interacts with and remodels the matrix. CXU™ remains investigational and its clinical effects in humans have not been established.
CXU™ is temperature responsive. At approximately body temperature, it is designed to transition from a flowable formulation into a stable gel-like scaffold.
CXU™ is designed around three phases: flow, set and regenerate. It begins as a flowable material, forms a gel near body temperature and provides a temporary ECM framework intended to support tissue in-growth and remodeling.
Cells respond to the physical and biochemical environment around them. Extracellular matrix architecture and mechanics can influence how cells attach, migrate, organize and respond to signals, which is why tissue structure is an important part of the regenerative environment.
A traditional breast implant is a permanent prosthetic device designed to maintain volume and shape. The B.R.E.A.S.T. concept is being developed as a temporary, resorbable ECM-based matrix intended to support host-tissue integration and remodeling. Clinical safety and effectiveness have not yet been established.
Biostimulators are generally used to provoke a biological response, such as new collagen production. A scaffold provides a physical matrix intended to support tissue organization and host interaction. Some materials may have both structural and biological effects, so distinctions should be based on mechanism and evidence rather than marketing terminology.
Signal-led approaches primarily aim to influence biological activity through growth factors, cytokines or other signaling mechanisms. A scaffold-led approach focuses first on the structural environment around cells. In tissue engineering, these approaches may be complementary rather than mutually exclusive.
The B.R.E.A.S.T. program combines 3D biofabricated architecture with CXU™ extracellular matrix technology. The scaffold is designed to provide temporary shape and structural support while creating an environment intended to support host-tissue integration and remodeling.
Conexeu is investigating CXU™ as an ECM scaffold for veterinary tissue-repair and wound applications, applying the same foundational flow-to-set scaffold concept being studied in human applications.
CXU™ is being developed as a flowable ECM scaffold that can conform to complex wound geometry, gel in place and provide a structural environment intended to support cell infiltration, vascular ingrowth and tissue formation.
Conexeu is investigating CXU™ as a flowable ECM scaffold for aesthetic soft-tissue applications. The development concept combines initial structural support with a temporary matrix intended to support tissue integration and remodeling. CXU™ remains investigational and its safety and effectiveness in humans have not been established.
Conexeu is exploring CXU™ as an investigational ECM scaffold for periodontal and related oral-health soft-tissue applications. The development concept focuses on temporary structural support and conformity to soft-tissue defects; clinical safety, effectiveness and regenerative benefit in humans have not been established.
Conexeu is evaluating CXU™-based 3D structures designed to combine defined physical architecture with a biomimetic ECM environment capable of supporting tissue integration and remodeling.
Hyaluronic acid fillers are primarily designed to add or restore volume by placing material within tissue. CXU™ is being developed as a temporary ECM scaffold intended to provide volume and structural support while also supporting tissue in-growth and remodeling. CXU™’s safety and effectiveness in humans have not yet been established.
Biostimulatory injectables generally rely on a biological response that leads to production of components such as collagen. CXU™ is being developed around a different concept: providing a multi-component ECM framework intended to support the broader tissue environment.
Many traditional aesthetic approaches primarily relax muscle activity, replace volume or stimulate a specific biological response. Regenerative approaches seek to support the underlying tissue environment itself.
Human durability has not yet been established. CXU™ is in preclinical development, so claims regarding duration of clinical effect would be premature.
The technology underlying CXU™ is grounded in more than a decade of university-based preclinical research and development.
In preclinical testing, CXU™ has been shown to form a gel at approximately 37°C within about 10 minutes. Clinical performance in humans has not yet been established.
No. Replacing volume addresses space or contour. Bioregeneration is focused on providing structural conditions intended to support integration, remodeling and tissue restoration.
B.R.E.A.S.T. is designed as a temporary, resorbable implanted scaffold rather than a permanent prosthetic breast implant. It remains an investigational preclinical concept, and its resorption, performance, safety and effectiveness in humans have not been established.
CXU™ is an investigational medical device candidate being evaluated as an ECM scaffold for aesthetic soft-tissue applications. Its ultimate regulatory classification, indications and claims have not been determined by FDA. Conexeu's development concept differs from conventional volume-only filling in that the temporary scaffold is also being studied for host-tissue interaction and remodeling.
Yes. CXU™ is being developed as a collagen-based, multi-component extracellular matrix scaffold designed to more closely mimic the structural complexity of native ECM than collagen alone.
CXU™ remains investigational. Availability for any veterinary use will depend on the applicable development and regulatory requirements for the intended application.
No. CXU™ is an investigational medical device candidate and has not been cleared or approved for marketing by the U.S. Food and Drug Administration.
The CXU™ formulation is being developed as a flowable, injectable scaffold that can conform to tissue spaces before gelling near body temperature.
CXU™ is not being designed as a permanent structure. The development intent is for the scaffold to be gradually resorbed over time as the local tissue environment remodels. The rate and extent of resorption, remodeling and durability in humans have not yet been established.
No. Collagen is an important component of extracellular matrix, but ECM is a more complex network containing multiple proteins, structural elements and sugars. Conexeu’s approach is designed to more closely reflect that complexity rather than relying on collagen alone.
Not exactly. Repair can restore continuity or close an injury without recreating the organization and function of the original tissue. Regeneration aims to restore tissue with greater structural and functional fidelity.
Tissue integration describes the interaction and incorporation of a material with surrounding host tissue. Remodeling refers to the biological process through which tissue and extracellular matrix change over time. These processes should be described in the context of the specific material and evidence available.
It reflects Conexeu's approach to designing an ECM-based structural environment intended to support tissue interaction and remodeling. Rather than focusing on a single ECM component, the development strategy uses a multi-component collagen-based scaffold inspired by features of native extracellular matrix.
ECM provides tissue with structure while helping regulate cellular behavior. It creates an environment that supports processes such as cell migration, adhesion, signaling and tissue organization.
It reflects Conexeu’s strategy of applying one core ECM technology across multiple tissue environments rather than developing a fundamentally different material for each application.
Preclinical development includes laboratory and animal research conducted before clinical performance is established in humans. These studies help researchers understand areas such as material behavior, biological response and potential safety.
Tissue regeneration can involve coordinated interactions among cells, biological signals and the surrounding extracellular matrix. Conexeu refers to these three elements as the Tissue Regeneration Trilogy, a tissue-engineering framework for explaining the role of structure alongside cells and signals.
CXU™ is supported by more than a decade of preclinical research spanning laboratory and animal models. Conexeu currently cites 11 peer-reviewed publications related to the underlying technology. All cited studies are preclinical and have not established safety or effectiveness in humans.
The scaffold is designed to provide temporary structural support that can permit host cell infiltration, vascular ingrowth, tissue integration and remodeling. These observations are based on preclinical research and have not yet been established clinically in humans.
The design intent is for the scaffold to provide temporary structural support and to be progressively resorbed while the surrounding tissue environment changes over time. Whether host-tissue integration and remodeling occur as intended, and with what clinical outcome, has not been established in humans.
The design intent is for CXU™ to provide temporary structural support and to be progressively resorbed over time. Preclinical studies evaluate how the material and surrounding tissue change during remodeling. Human resorption kinetics, durability and clinical outcomes have not yet been established.
Injury, disease or other tissue changes can disrupt ECM architecture. When the scaffold is compromised, tissue may lose some of the structure and organized environment needed for repair and regeneration.
Regeneration is a coordinated process, so disruption to cells, signaling or structural matrix can change the environment in which repair occurs. The impact varies by tissue and injury, but the framework helps explain why stimulating one component alone may not recreate the full tissue environment.
Published preclinical research related to the underlying platform has reported observations including scaffold interaction with host tissue, cellular infiltration, vascular ingrowth, remodeling and local host response in laboratory or animal models. Conexeu has also completed additional current preclinical work, but detailed findings and quantitative histologic endpoints should be described only as publicly disclosed. Preclinical findings may not predict performance in humans.
It is a three-dimensional scaffold designed not simply to occupy space but to provide temporary structural architecture that can interact with host tissue and potentially support remodeling and regeneration.
A biomimetic ECM is designed to reproduce selected structural or functional features of native extracellular matrix. Conexeu uses 'biomimetic' to describe the design intent of CXU™, a multi-component collagen-based ECM scaffold. The degree to which any biomaterial reproduces native ECM features should be supported by material characterization and preclinical evidence.
An ECM scaffold is a structural framework designed to support cells and tissue as repair or regeneration occurs. Depending on its design, a scaffold may provide temporary architecture that is gradually remodeled or resorbed as host tissue develops.
Bioregeneration is the process of providing the structural support tissue needs for regeneration. Conexeu uses the term to describe creating the conditions that allow cells, biological signals and the extracellular matrix scaffold to work together in support of tissue restoration.
Bioregenerative aesthetics focuses on creating biological and structural conditions that support the body’s own tissue-restoration processes. Conexeu’s approach centers on rebuilding the ECM foundation those processes depend on.
Conexeu uses 'bioregenerative breast reconstruction' to describe an investigational concept in which a temporary biological or biomimetic scaffold is used to provide structural support while host-tissue interaction and remodeling are evaluated, rather than relying solely on a permanent prosthetic implant. Clinical regeneration has not been established.
The development program is evaluating whether a flowable ECM scaffold can provide structural support, integrate with host tissue and support tissue remodeling processes across different tissue applications.
CXU™ is Conexeu Sciences’ investigational collagen-based extracellular matrix medical device candidate. It is being developed as a temporary structural scaffold designed to support tissue integration, remodeling and regeneration.
The extracellular matrix, or ECM, is the structural network surrounding cells within tissue. It provides physical support and helps create the environment in which cells organize, communicate and function.
ECM contains multiple structural proteins and other biological components, including collagen, elastin, glycoproteins and glycosaminoglycans. Its exact composition varies by tissue.
Regenerative aesthetics is an emerging area of aesthetic medicine focused on supporting the repair, restoration or regeneration of tissue rather than solely altering appearance or replacing lost volume.
Soft-tissue restoration focuses on rebuilding or supporting the structure of tissue that has been lost, altered or weakened. In aesthetics, this may include restoring physical support while also creating conditions intended to support tissue integration and remodeling.
B.R.E.A.S.T.™ is Conexeu's investigational 3D biofabricated breast-reconstruction development program using CXU™-based material concepts. It is being explored as a temporary, resorbable scaffold intended to provide structural architecture while preclinical research evaluates host-tissue interaction and remodeling. It has not been studied for clinical safety or effectiveness in humans.
Biostimulation generally describes approaches intended to stimulate a biological response, such as new collagen production. Bioregeneration takes a broader structural approach, providing an extracellular matrix framework designed to support cells, signaling, tissue integration and remodeling.
Regenerative medicine is a broad field encompassing approaches such as biomaterials, tissue engineering and cell-based therapies. Bioregeneration describes Conexeu’s structural approach to supporting the environment tissue needs to regenerate.
Tissue regeneration is the biological process of restoring tissue. Bioregeneration, as Conexeu uses the term, focuses on creating the structural conditions that help enable that regenerative process.
Volumization adds or restores physical volume. Tissue regeneration involves biological processes that rebuild tissue structure and function. An approach can potentially provide initial structural volume while also being designed to support regenerative processes.
Tissue restoration focuses on rebuilding or supporting the underlying tissue architecture rather than addressing appearance solely through temporary volume replacement.
Conexeu uses 'biomimetic' to describe CXU™'s design as a multi-component, collagen-based ECM scaffold intended to reproduce selected structural features of native extracellular matrix. The term describes design intent and material characteristics, not an established clinical equivalence to native tissue.
CXU™ provides the ECM-based material foundation for the B.R.E.A.S.T. program. In this application, the material is being explored within a 3D biofabricated structure designed to combine physical architecture with a biomimetic tissue environment.
As in human tissue, extracellular matrix provides structural support and helps create the environment in which cells migrate, organize and participate in repair. Veterinary tissue injury can therefore create the same need for structural support during healing and remodeling.
Tissue regeneration depends on coordinated biology. Cells carry out repair and rebuilding, biochemical signals help direct cellular activity and the extracellular matrix scaffold provides the structural environment in which those processes occur. The framework is useful for explaining why regeneration is not driven by any one component alone.
B.R.E.A.S.T. is an investigational development program. The technology remains in preclinical evaluation and is not approved or cleared for clinical use.
Aging can alter skin, fat, muscle and extracellular matrix architecture. Changes in collagen organization, tissue elasticity and underlying volume can contribute to laxity, deflation and changes in contour. These changes create interest in approaches that address the tissue environment as well as visible appearance.
Conexeu is exploring CXU™ for soft-tissue restoration in aesthetic medicine, including tissue changes associated with aging and significant weight loss. Specific clinical uses and outcomes will require human clinical evaluation and applicable regulatory review.
Conexeu is exploring CXU™ in veterinary tissue-repair and wound settings. The specific applications, species and clinical uses will depend on continued development and evaluation.
3D biofabrication is being explored across tissue-engineering applications where both shape and biological integration matter. Conexeu is evaluating CXU™-based approaches in selected soft-tissue applications, with specific uses dependent on preclinical and clinical development.
CXU™ remains an investigational medical device candidate in preclinical development. No commercial availability date should be assumed until applicable development and regulatory requirements have been completed.
3D architecture can provide defined shape and physical organization, while an ECM-based material can provide a biologically relevant structural environment. Conexeu is exploring the combination to create temporary matrices designed to support host-tissue integration and remodeling.
Veterinary wounds can be irregular in shape and depth. A flowable material can conform to complex tissue spaces before setting into a temporary scaffold designed to maintain contact with surrounding tissue and support healing processes.
Its flowable state allows CXU™ to conform to irregular tissue spaces and maintain close contact with surrounding tissue before it sets.
ECM helps provide the structural framework that supports skin and underlying soft tissue. Changes in ECM integrity can therefore contribute to changes in tissue structure, contour and quality.
Periodontal ECM provides structural support for the soft tissues involved in attachment and healing. Aging, bacteria, chronic stress or trauma can disrupt that framework.
A scaffold provides physical architecture, but its relevance extends beyond simply occupying space. Its composition, structure and interaction with host tissue can influence cell attachment, migration, organization and remodeling. The specific biological response depends on the scaffold and must be supported by evidence.
The same foundational CXU™ technology is being explored across multiple applications, including aesthetics, wound care, oral health, animal health and 3D tissue applications. Conexeu describes the approach as one formula, one device and multiple potential applications.
ECM provides the structural environment in which cells migrate, organize and participate in repair. Trauma, burns or surgery can destroy that matrix along with the tissue itself.
ECM provides the structural framework around cells and helps create the conditions necessary for organized tissue repair. When that framework is disrupted or lost, the environment needed for regeneration can also be compromised.
Collagen provides important structural support, but native ECM contains a broader combination of proteins, glycoproteins, glycosaminoglycans and other components. CXU™ is being developed as a multi-component collagen-based scaffold intended to provide a broader structural environment than collagen alone. Cells, Signals + Scaffold
Cells do not function in isolation. They interact with biological signals and the extracellular matrix around them. A supportive ECM provides physical architecture as well as an environment in which cells can migrate, organize and participate in tissue repair.
Complex wounds may have irregular shapes and depths that make complete contact challenging. A flowable material can adapt to those spaces before setting into a stable scaffold.
Cells and signals act within a physical tissue environment. Restoring or providing structure may help establish the architecture in which cellular and signaling processes occur. This is a scientific rationale for studying scaffold-based approaches, not evidence that a specific scaffold produces a particular clinical outcome.
3D biofabrication allows researchers to create defined shapes and internal architecture while using biomaterials selected for tissue interaction. In the B.R.E.A.S.T. program, Conexeu is exploring whether that combination can provide temporary structural support for tissue integration and remodeling.
Conexeu is not affiliated with, endorsed by, or sponsored by any third-party brand referenced on this site. Ozempic®, Wegovy®, Dysport®, Sculptra®, Restylane®, Radiesse®, Xeomin®, Belotero®, Instalift®, Cetaphil®, Differin®, Proactiv® and Epiduo® are registered trademarks of their respective owners. CXU™, Ten-Minute Tissue™, B.R.E.A.S.T.™ and Architecting Bioregeneration™ are trademarks of Conexeu Sciences Inc.